Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - The market anticipates Absci Corporation (ABSI) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $0.19 per share, reflecting a year-over-year change of +13.6%, while revenues are expected to reach $2.32 million, an increase of 82.7% from the previous year [3]. - The consensus EPS estimate has been revised 11.36% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Absci is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +12.07%, suggesting a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which indicates a neutral outlook [12]. Historical Performance - In the last reported quarter, Absci was expected to post a loss of $0.23 per share but delivered a loss of -$0.21, resulting in a surprise of +8.70% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Immunome, Inc. is expected to report a loss of $0.52 per share for the same quarter, with revenues projected at $2.47 million, up 4.7% year-over-year [18]. - Immunome's consensus EPS estimate has been revised down by 0.7% over the last 30 days, but it has an Earnings ESP of +15.92%, combined with a Zacks Rank of 4, indicating challenges in predicting an earnings beat [19].